Robust Genomic Copy Number Predictor of Pan Cancer Metastasis – Pearlman Et Al

Robust Genomic Copy Number Predictor of Pan Cancer Metastasis – Pearlman Et Al

Robust Genomic Copy Number Predictor of Pan Cancer Metastasis – Pearlman et al S1 Table. Left and Center: Logistic regression and Cox proportional hazards models predict progression to metastasis for full set (variable number by cohort) and panMPS (295) genes. Right: Linear regression model predicting correlation (r2) between MPS and panMPS. Linear Logistic Regression Cox Regression Regres Variable sion Cohort s Conc Odds Hazard P 95% CI AUC 95% CI - P r2 Ratio Ratio index MPS 2.03 2.00 to (320 5.39 0.001 0.69 4.85 0.72 0.0005 0.97 MSK_Prost to15.49 11.77 genes) ate 2.21 to 2.18 to panMPS 6.01 0.001 0.71 5.42 0.74 0.0003 0.97 17.89 13.49 MPS 2.36 to 1.20 to (351 10.99 0.004 0.72 3.54 0.62 0.02 0.99 Duke_Pros 65.88 10.44 genes) tate 2.39 to 1.15 to panMPS 11.39 0.004 0.72 3.41 0.62 0.03 0.97 70.36 10.12 MPS 2.87 to 1.04 to (352 44.36 0.02 0.75 4.01 0.59 0.04 0.99 Montefiore 2005.4 15.44 genes) _TNBC 2.91 to 1.03 to panMPS 44.74 0.02 0.75 4.06 0.59 0.05 0.96 1927.9 16.04 42.79 MPS 3.78× to 1.04 to (353 0.006 0.94 4.65 0.65 0.04 0.96 103 1.04×10 20.63 genes) MSK_Lung 7 41.5 3.45× 1.31 to panMPS 0.006 to1.26× 0.94 6.57 0.67 0.02 0.96 103 33.04 107 S2 Table. Logistic regression models predicting progression to metastasis for prostate cancer based on panMPS and clinical variables MSK Prostate CA (n=182, mPT=25, Duke Prostate CA (n=61, mPT=37, Cohort iPT=157) iPT=24) Odds Odds Variable P 95% CI AUC P 95% CI AUC Ratio Ratio Univariate panMPS 5.98 0.001 2.12 to 18.57 0.7 11.84 0.002 2.78 to 67.71 0.75 Preop PSA 1.06 0.02 1.02 to 1.11 0.66 1.1 0.08 1.01 to 1.21 0.61 Biopsy 3.82 0.02 1.21 to 11.10 0.58 3.96 0.09 0.89 to 27.84 0.59 Gleason Clinical Stage 2.3 0.06 0.98 to 5.59 0.6 4 0.1 0.86 to 28.88 0.61 1.3×10- 20.51 to Path Gleason 68 0.81 7.5 0.01 1.83 to 51.3 0.66 10 280.1 Path Stage 5.19 0.001 2.12 to 14.08 0.7 0.47 0.23 0.13 to 1.63 0.57 %Genome 1.17 1.4×10-5 1.09 to 1.26 0.74 1.04 0.12 1.00 to 1.12 0.8 Inst. Multivariate panMPS 4.09 0.01 1.38 to 13.19 0.75 14.32 0.003 2.7 to 103.6 0.78 Preop PSA 1.04 0.05 1.01 to 1.1 1.1 0.06 1.01 to 1.24 panMPS 5.09 0.003 1.8 to 15.54 0.73 6.06 0.06 2.4 to 70.4 0.68 Biopsy 2.32 0.15 0.69 to 7.17 1.18 0.88 1.03 to 47.04 Gleason panMPS 5.51 0.001 1.99 to 16.59 0.73 4.42 0.13 0.71 to 34.06 0.72 Clinical Stage 1.93 0.15 0.79 to 4.83 2.76 0.26 0.52 to 21.2 panMPS 1.5 0.55 0.39 to 5.88 0.86 7.45 0.03 1.4 to 49.38 0.77 1.21×10- 15.57 to Path Gleason 56.8 4.83 0.06 1.1 to 34.44 8 263.14 panMPS 3.93 0.01 1.43 to 11.94 0.77 10.59 0.01 2.18 to 65.6 0.73 Path Stage 3.83 0.006 1.49 to 10.74 0.59 0.45 0.15 to 2.32 panMPS 1.79 0.32 0.59 to 5.97 0.75 8,45 0.03 1.41 to 62.2 0.73 %Genome 1.15 0.001 1.06 to 1.25 1.01 0.53 0.98 to 1.07 Inst. panMPS 1.49 0.52 0.45 to 5.39 0.8 9.93 0.02 1.47 to 85.45 0.78 Preop PSA 1.03 0.21 1.00 to 1.09 1.1 0.06 1.01 to 1.24 %Genome 1.14 0.004 1.05 to 1.25 1.02 0.5 0.98 to 1.08 Inst. panMPS 3.7 0.03 1.2 to 11.93 0.76 8.6 0.04 1.25 to 90.53 0.74 Biopsy 2.2 0.21 0.59 to 7.1 1.35 0.78 0.17 to 13.8 Gleason Preop PSA 1.04 0.05 1.01 to 1.09 1.11 0.09 1.01 to 1.28 panMPS 4.71 0.01 1.66 to 14.48 0.75 4.47 0.13 0.70 to 36.93 0.71 Biopsy 2.24 0.17 0.66 to 6.97 0.93 0.95 0.12 to 8.55 Gleason Clinical Stage 1.88 0.17 0.77 to 4.76 2.8 0.26 0.51 to 22.16 panMPS 1.29 0.71 0.34 to 4.99 0.85 6.88 0.03 1.27 to 45.95 0.77 8.69×10- 12.71 to Path Gleason 47.21 4.91 0.06 1.08 to 35.13 8 224.2 Path Stage 2.87 0.08 0.87 to 9.88 0.56 0.42 1.13 to 2.31 panMPS 3.56 0.03 1.16 to 11.62 0.78 6.97 0.04 0.94 to 77.9 0.76 Biopsy 2.15 0.22 0.59 to 6.97 1.07 0.08 0.11 to 11.94 Gleason Clinical Stage 1.41 0.48 0.54 to 3.71 2.73 0.46 0.46 to 22.54 Preop PSA 1.04 0.07 1.01 to 1.08 1.11 0.29 1.01 to 1.29 panMPS 3.5 0.03 1.16 to 11.2 0.79 5.68 0.13 0.66 to 68.5 0.76 Biopsy 2.2 0.22 0.60 to 7.51 1.34 0.82 0.12 to 31.9 Gleason Clinical Stage 1.37 0.52 0.52 to 3.61 2.39 0.37 0.38 to 20.3 Preop PSA 1.04 0.06 1.01 to 1.09 1.1 0.13 0.99 to 1.27 3.85×10-104 to Age 0.51 0.35 0.13 to 2.49 7.85×106 0.99 NA S3 Table. Cox proportional hazards model of panMPS and its association with metastasis-free survival for prostate cancer based on panMPS and clinical variables MSK Prostate CA (n=222, mPT=25, Cohort Duke Prostate CA (n=76, mPT=37, iPT=39) iPT=197) Hazard Conc Hazard Conc Variables 95% CI P 95% CI P Ratio -indx Ratio -indx Univariate panMPS 4.2 1.67 to 10.4 0.7 0.002 3.9 1.48 to 10.4 0.63 0.01 7.60×1 Preop PSA 1.01 1.00 to 1.01 0.63 1 0.97 to 1.03 0.51 0.98 0-5 Biopsy Gleason 3.11 1.24 to 7.83 0.73 0.02 1.63 0.71 to 3.72 0.65 0.25 Clinical Stage 1.75 0.78 to 3.91 0.65 0.17 0.48 0.21 to 1.09 0.64 0.08 9.90×1 Path Gleason 17.34 7.63 to 39.4 0.97 1.67 0.84 to 3.34 0.71 0.14 0-12 Path Stage 3.99 1.67 to 9.58 0.82 0.002 0.61 0.23 to 1.57 0.57 0.3 3.30×1 %Genome Inst. 1.11 1.07 to 1.16 0.67 1.01 0. 99 to 1.02 0.66 0.2 0-7 Multivariate panMPS 4.31 1.72 to 10.8 0.74 0.002 3.52 1.18 to 10.5 0.71 0.02 Preop PSA 1.01 1.00 to 1.01 0.0002 0.99 1.02 to 1.12 0.7 panMPS 3.77 1.49 to 9.51 0.72 0.005 3.13 1.06 to 9.29 0.66 0.04 Biopsy Gleason 2.18 0.83 to 5.69 0.1 1.86 0.88 to 3.93 0.1 panMPS 4.59 1.83 to 11.6 0.71 0.001 2.25 0.62 to 8.17 0.6 0.22 Clinical Stage 1.81 0.81 to 4.03 0.15 1.86 0.79 to 4.34 0.15 panMPS 1.79 0.69 to 4.65 0.86 0.23 2.97 0.94 to 9.41 0.64 0.06 2.74×1 Path Gleason 14.34 5.96 to 34.5 1.29 0.62 to 2.69 0.5 0-9 panMPS 2.96 1.19 to 7.33 0.76 0.02 3.19 1.05 to 9.64 0.62 0.04 Path Stage 3.03 1.22 to 7.55 0.02 0.73 0.27 to 1.91 0.5 panMPS 1.37 0.47 to 3.97 0.71 0.56 3.26 1.08 to 9.8 0.62 0.04 %Genome Inst.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    32 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us